Skip to main content
. 2020 Nov 11;8(2):e001662. doi: 10.1136/jitc-2020-001662

Table 1.

Demographics for stage III VRP-CEA vaccine study

Characteristic N (%)
Median age at study entry 53 (IQR 43–62)
Gender (female/male) 8 (67)/4 (33)
Race (Caucasian/non-Caucasian) 11 (92)/1 (8)
Site (colon/rectum) 10 (83)/2 (17)
Stage
 IIIA 1 (8)
 IIIB 8 (67)
 IIIC 3 (25)
Adjuvant therapy
 Chemotherapy 10 (83)
 Chemotherapy and radiotherapy 2 (17)
Time from surgery to study enrollment (months) 10.5 (IQR 8.8–11.3)

CEA, carcinoembryonic antigen; VRP, virus-like replicon particle.